Fig. 6

Absorption percentage per hour (A) of GLV, RHV, VIT, RUT and HP in HLF under different conditions in the rat intestinal loop. (A) HLF doses (5, 10 and 20 mg), ^*p < 0.05, ^**p < 0.01 and ^***p < 0.001 compared to 5 mg group; ^#p < 0.05, ^##p < 0.01and ^###p < 0.001 compared to 10 mg group. (B) pH conditions (4, 6 and 8), ^*p < 0.05, ^**p < 0.01 and ^***p < 0.001 compared to pH 4 group; ^#p < 0.05, ^##p < 0.01and ^###p < 0.001 compared to pH 6 group. (C) w or w/o ligation of bile duct and rinsing of intestine, ^*p < 0.05, ^**p < 0.01 and ^***p < 0.001 compared to Ligation of bile duct + rinsing of intestine group; ^#p < 0.05, ^##p < 0.01and ^###p < 0.001 compared to Ligation of bile duct + without rinsing of intestine group. (D-G) Absorption enhancers (CBS and SDS), P-gp inhibitors (VP and DIG), BSEP inhibitor (RIF) and SGLT1 inhibitor (MAN), ^*p < 0.05, ^**p < 0.01 and ^***p < 0.001 compared to Control group; ^#p < 0.05, ^##p < 0.01 and ^###p< 0.001 compared to CBS or VP group. Concentration of HLF in the perfusion solution were all 1 mg·mL⁻¹. The perfusion volume of HLF solution were all 10 mL. CBS, cow bile salt; SDS, sodium dodecyl sulfate; VP, verapamil hydrochloride; DIG, digoxin; RIF, rifampicin; MAN, mannitol. Data are represented as mean ± SD, n = 5.